**Trader sentiment for Intuitive Surgical's Q3 2026 da Vinci procedure growth centers on the company's maintained 13.5–15.5% full-year guidance, with management expecting results near the midpoint.** Q2 results showed 15% da Vinci growth (12% U.S., 20% OUS), supported by general surgery adoption, da Vinci 5 placements, and Ion/SP platforms, though offset by tougher year-over-year comparisons from Q3 2025's 19% growth and U.S. headwinds including ACA subsidy changes. International diversification via India, Japan reimbursement expansions, and SP utilization gains provides ballast against China tender weakness and domestic competition. With Q3 earnings imminent, market-implied odds cluster around the 10–17.5% range as traders weigh recurring revenue leverage from installed-base utilization against potential sequential moderation.